AstraZencea Pharma India is trading lower by 2.5% to Rs 1,124 on reports that the capital market regulator directed stock exchanges to monitor the delisting process of the drug maker.
The stock opened at Rs 1,155 and touched a low of Rs 1,111 on the National Stock Exchange (NSE). A combined around 24,000 shares changed hands on the counter till early morning deals on NSE and BSE.
The Securities and Exchange Board of India (Sebi) has said AstraZeneca can purchase shares in the delisting offer only after seeking approval of the stock exchanges, the Business Standard report suggests.
Sebi probe raised suspicion that the pharma company might have collaborated with the Elliott group to facilitate delisting, added report.
The Elliott group entities cornered a large stake in the company during its Offer for Sale in May 2013, where AstraZeneca's foreign promoters sold 14.99% stake.
The stock opened at Rs 1,155 and touched a low of Rs 1,111 on the National Stock Exchange (NSE). A combined around 24,000 shares changed hands on the counter till early morning deals on NSE and BSE.
The Securities and Exchange Board of India (Sebi) has said AstraZeneca can purchase shares in the delisting offer only after seeking approval of the stock exchanges, the Business Standard report suggests.
Sebi probe raised suspicion that the pharma company might have collaborated with the Elliott group to facilitate delisting, added report.
The Elliott group entities cornered a large stake in the company during its Offer for Sale in May 2013, where AstraZeneca's foreign promoters sold 14.99% stake.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%